<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01888237</url>
  </required_header>
  <id_info>
    <org_study_id>si111/2013</org_study_id>
    <nct_id>NCT01888237</nct_id>
  </id_info>
  <brief_title>High Dose PPI Triple Therapy Versus Sequential Therapy for Helicobacter Pylori Eradication</brief_title>
  <official_title>Randomized Open Labeled Clinical Trial: a Comparative Study of 10-day High Dose PPI-based Triple Therapy vs. 10-day Sequential Therapy for Helicobacter Pylori Eradication in Functional Dyspepsia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda Pharmaceuticals International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy between 1-day high dose PPI-based triple&#xD;
      therapy vs. 10-day sequential therapy for Helicobacter pylori eradication in functional&#xD;
      dyspepsia patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      Helicobacter pylori (HP) play an important role in the pathogenesis of chronic gastritis,&#xD;
      peptic ulcer diseases as well as gastric cancer. Helicobacter pylori eradication is a&#xD;
      critical strategy to reduce aforementioned conditions. Proton-pump inhibitor (PPI)-based&#xD;
      triple therapy (Standard dose PPIs+ Clarithromycin 1g/D + Amoxycillin 2g/D or Metronidazole&#xD;
      800 mg/D) is recommended as a frontline treatment in current guidelines for HP eradication,&#xD;
      both from Thai and Second Asia-Pacific Consensus Guideline for H.pylori 2009. Unfortunately,&#xD;
      it has been reported an unacceptably low eradication rate (&lt;85%) of this regimen in a&#xD;
      tertiary care hospital in Thailand. This occurrence is not surprised as the worldwide&#xD;
      efficacy of this regimen had decreased to 50-75%. Of this, Clarithromycin resistance has been&#xD;
      a major cause of the treatment failure.&#xD;
&#xD;
      Sequential therapy (ST) which consists of standard dose PPIs + amoxycillin 2 g/D for 5 days&#xD;
      with 5 additional days of clarithromycin 1g/D + metronidazole 800 mg/D has been proposed to&#xD;
      increase an efficacy in HP eradication. A recent meta-analysis of over three thousand&#xD;
      population revealed a higher eradication rate over PPI-based triple therapy (TT). A&#xD;
      consistent finding from Thailand was reported an impressive success rate of ST in HP&#xD;
      eradication up to 95%. Therefore, more updated guidelines recommend using ST, not TT, as the&#xD;
      first line regimen. However, ST is a complicated regimen for the patients to be followed.&#xD;
      This might cause a low adherence rate in clinical practice as well as development of drug&#xD;
      resistance in near future.&#xD;
&#xD;
      Interestingly, PPI is a pivotal in all regimens in HP eradication. There is evidence that the&#xD;
      sustained higher intragastric pH is a major therapeutic determinant of HP eradication. Other&#xD;
      factors including inflammatory cytokine polymorphisms, especially the IL-1B-511 T/T genotype&#xD;
      and PPIs metabolizer, are the determinants of eradication by affecting gastric acid secretion&#xD;
      and mucosal inflammation. Hence, higher dosage of PPIs is justified to eradicate HP. This has&#xD;
      been shown in a recent meta-analysis that high dose PPI is better than standard dose PPI&#xD;
      triple therapy in HP eradication of HP. Our study aims to compare the efficacy of ST to high&#xD;
      dose PPI TT. Secondary outcomes include comparisons in the adherence and adverse events&#xD;
      between both regimens, to determine the prevalence of clarithromycin resistance HP and&#xD;
      determine improvement of dyspeptic symptoms after HP eradication&#xD;
&#xD;
      Primary Aim/Objective:&#xD;
&#xD;
      To evaluate eradication rates of Helicobacter pylori infection in functional dyspepsia&#xD;
      patients amongst Thai population, compare between a 10-day sequential regimen (lansoprazole&#xD;
      30 mg b.d. plus amoxicillin 1000 mg b.d. for 5 days then lansoprazole 30 mg b.d.,&#xD;
      metronidazole 400 mg b.d. and clarithromycin 500 mg b.d. for the remaining 5 days) with a&#xD;
      10-day high dose PPI-based triple regimen (lansoprazole 60 mg b.d. plus clarithromycin 500 mg&#xD;
      b.d. and amoxycillin 1000 mg b.d. for 10 days)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication rate</measure>
    <time_frame>4 weeks after the end of intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adherence rate/adverse events</measure>
    <time_frame>up to 2 weeks after intervention initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of clarithromycin resistance HP</measure>
    <time_frame>4 weeks after the end of intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic responses regarding dyspeptic symptoms after HP eradication</measure>
    <time_frame>Baseline, week 4,8 and 24 after intervention completion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Dyspepsia</condition>
  <condition>Helicobacter-associated Gastritis</condition>
  <condition>Stomach Disorders</condition>
  <arm_group>
    <arm_group_label>Sequential therapy (ST)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 day Sequential therapy: lansoprazole 30 mg b.d. plus amoxicillin 1000 mg b.d. for 5 days then lansoprazole 30 mg b.d., metronidazole 400 mg b.d. and clarithromycin 500 mg b.d. for the remaining 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose PPI triple therapy(TT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 day high dose PPI triple therapy: lansoprazole 60 mg b.d. plus clarithromycin 500 mg b.d. and amoxycillin 1000 mg b.d. for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Double dose of PPI</intervention_name>
    <description>Lansoprasole (30mg) 2 tab oral BID</description>
    <arm_group_label>High dose PPI triple therapy(TT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sequence of drug use</intervention_name>
    <description>lansoprazole 30 mg b.d. for 10 days amoxicillin 1000 mg b.d. (day 1 to day 5) metronidazole 400 mg b.d. (day 6-day 10) and clarithromycin 500 mg b.d. (day 6-day 10)</description>
    <arm_group_label>Sequential therapy (ST)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Functional dyspepsia patients (Rome III) with rapid urease test positive&#xD;
&#xD;
          -  Age â‰¥ 18 years old&#xD;
&#xD;
          -  No history of HP eradication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recent use of PPI, H2RA, NSAID, Antibiotics within 2 weeks&#xD;
&#xD;
          -  Currently use of anticoagulants or ketoconazole&#xD;
&#xD;
          -  C/I for gastric biopsy&#xD;
&#xD;
          -  History of gastric surgery&#xD;
&#xD;
          -  Comorbidity: ESRD, advanced cirrhosis, AIDS, stroke (bed ridden)&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Allergy to studied drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>monthira maneerattanaporn</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of gastroenterology, Department of Medicine, Siriraj hospital 2, Pran-nok, Bangkoknoi, Bangkok, Thailand, Mahidol University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of gastroenterology, Department of Medicine, Siriraj hospital</name>
      <address>
        <city>Bangkok Noi</city>
        <state>Bangkok,</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>June 25, 2013</study_first_submitted>
  <study_first_submitted_qc>June 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2013</study_first_posted>
  <last_update_submitted>April 9, 2015</last_update_submitted>
  <last_update_submitted_qc>April 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>Monthira Maneerattanaporn</investigator_full_name>
    <investigator_title>Lecturer</investigator_title>
  </responsible_party>
  <keyword>Dyspepsia</keyword>
  <keyword>Helicobacter pylori</keyword>
  <keyword>Clarithromycin resistance</keyword>
  <keyword>Other Specified Disorders of Function of Stomach</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastritis</mesh_term>
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

